Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.60 |
| ▸ | FYN | P06241 | 1/20 | 0.60 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.60 |
| ▸ | GRB2 | P62993 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | GAA | P10253 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | GLA | P06280 | 2/20 | 0.58 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.58 |
| ▸ | BCHE | P06276 | 5/20 | 0.58 |
| ▸ | ACHE | P22303 | 5/20 | 0.58 |
| ▸ | HSD17B3 | P37058 | 6/20 | 0.53 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2760317 | 0.96 | LCK (0.61) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL10035521 | 0.92 | LCK (0.64) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL723311 | 0.88 | LCK (0.63) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL532562 | 0.88 | BCHE (0.60) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL724773 | 0.88 | LCK (0.63) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL725498 | 0.86 | BCHE (0.58) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL8097195 | 0.85 | LCK (0.65) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL16745455 | 0.84 | BCHE (0.45) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL24062584 | 0.83 | ALDH1A1 (0.60) | LCKFYNAKR1B1GRB2ALDH1A1 | |
| SCHEMBL716590 | 0.83 | ALDH1A1 (0.57) | LCKFYNAKR1B1GRB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2191006-B1 | METHODS FOR ASSAYING ALPHA-L-IDURONIDASE ENZYMATIC ACTIVITY | UNIV WASHINGTON (US) | 2012-11-21 | — | — | EP | disclosed |
| US-20120052519-A1 | METHODS FOR ASSAYING ALPHA-L-IDURONIDASE ENZYMATIC ACTIVITY | UNIVERSITY OF WASHINGTON (US) | 2012-03-01 | — | — | US | disclosed |
| US-20100209951-A1 | METHODS FOR ASSAYING ALPHA-L-IDURONIDASE ENZYMATIC ACTIVITY | UNIVERSITY OF WASHINGTON THROUGH ITS CENTER FOR COMMERCIALIZATION (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120052519-A1 | METHODS FOR ASSAYING ALPHA-L-IDURONIDASE ENZYMATIC ACTIVITY | IDUA, GAA, ENGASE | LCK 4717/4885FYN 4354/4885AKR1B1 1920/4885 |
| US-20100209951-A1 | METHODS FOR ASSAYING ALPHA-L-IDURONIDASE ENZYMATIC ACTIVITY | IDUA, GAA, ENGASE | LCK 4717/4885FYN 4354/4885AKR1B1 1920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.